Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Capital wins contracts; 4D pharma pauses enrolment

Fri, 01st Jul 2022 20:05

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Friday and not separately reported by Alliance News:

----------

ADM Energy PLC - London-based natural resource investor - Notes PetroNor E&P Ltd extends the long-stop date for Panoro Energy ASA to sell 100% ownership in OML-113 to PetroNor. Expects transaction to complete within 14 days. "ADM Energy holds a 9.2% profit interest in the Aje field in OML 113, which covers an area of 835 square kilometres offshore Nigeria. Aje has multiple oil, gas and gas condensate reservoirs in the Turonian, Cenomanian and Albian sandstones with five wells drilled to date. It currently has two producing wells, Aje-4 in the Cenomanian and Aje-5 in the Turonian," ADM explains.

----------

Primorus Investments PLC - London-based investment firm focused on small and mid cap firms in financial services, technology and natural resources - Notes investee Alteration Earth PLC begins trading on the Main Market of the London Stock Exchange. Primorus holds 28% of ALTE's share capital, at 5.0 million shares, having invested GBP100,000 in its seed round, and GBP250,000 in its subscription round. Also says it has acquired 1.0 million shares in AIM-listed Landore Resources Ltd at 22.60 pence each, for GBP225,978 in total. Landore is a holding company for its 100% owned subsidiary Landore Resources Canada Inc, which is an acquirer, developer and explorer of precious and base metal projects in Eastern Canada.

----------

San Leon Energy PLC - Dublin-based oil and gas production, development and exploration company focused on Nigeria - In discussions with Decklar Resources Ltd to extend the option period for the firm to increase its shareholding in Decklar to 15% from 11%. This would entail a further loan of USD2.5 million, and the previous deadline for the option was Thursday.

----------

4D Pharma PLC - Leeds, England-based pharmaceutical company - Pauses recruitment of new patients in its ongoing clinical studies, citing the firm being put into administration as the reason for doing so. Will affect three studies into MRx0518, one study of MRx-4DP0004, and one study of MRx0005 or MRx0029. "4D pharma is working with the administrators to enable an exit from administration as soon as possible and, in the event that the company does exit administration, currently plans to recommence recruitment so long as additional capital funding is secured. Further announcements will be made in due course," the firm says.

----------

Petropavlovsk PLC - Russian gold producer - Says MHA MacIntyre Hudson, the UK member of Baker Tilly International has resigned as its external auditor. Had changed its accounting reference period to February 28 year-end from December 31, as it considered completion of the audit "unlikely". The firm maintains this position.

----------

PCF Group PLC - London-based specialist bank - Signs agreement with majority shareholder Somers Ltd for subscription of around GBP1.4 million in 27.9 million new shares. Somers' stake in the firm will increase to 73.2% from 70.8% after the new shares are admitted, expected on Monday. Reiterates intention to raise additional capital through open offer for up to EUR8 million, in which Somer is not expected to participate.

----------

Seed Innovations Ltd - Guernsey-based wellness and life sciences company - Notes announcement from investee Little Green Pharma Ltd that in the nine months to March 31, its revenue grew by 50% year-on-year. Seed holds a 3.1% stake in LGP. "It has been an exceptional year for LGP, as it continued its growth in Australia and advanced its strategy to expand into other markets. During the period, LGP became a leading cannabis company in the European Union with its GMP-licensed Danish facility and its continued development of its supply channels into new markets such as Italy and Denmark," says Alfredo Pascual, vice president of Investment Analysis.

----------

Pembridge Resources PLC - London-based copper-focused mining company - Receives second repayment of CAD1 million due to it from Minto Metals Corp. Pembridge lent CAD4 million in total to Minto to fund Minto's surety account, in 2019 and 2020. The loan has an interest rate of 8%, and is due in quarterly instalments of CAD1 million over 2022. The first repayment was received in March, as planned. "With this second CAD1 million repayment from Minto, Pembridge is in a much stronger cash position, which will improve further with the repayments which are still to come," says Chair & Chief Executive Officer Gati Al-Jebouri.

----------

Capital Ltd - Africa-focused mining services provider - Wins new contracts for drilling and laboratory services. Its Tanzanian subsidiary CMS (Tanzania) Ltd wins a three-year comprehensive drilling services contract with AngloGold Ashanti Ltd. The contract "further cements" the long-term relationship between the two parties, which started back in 2006. Expects the new deal to generate USD150 million over the three-year term, which makes it the second-largest award of new business in Capital's history, the firm says. Also wins first contract with B2Gold Corp at Fekola gold mine, for reverse circulation drilling services, and a two-year extension to MSALABS contract for onsite laboratory services with Kinross at the Tasiast gold mine in Mauritania. "We are pleased to maintain our long-standing relationship with AngloGold Ashanti at their Geita Gold Mine with the award of this revised and expanded long-term contract that will extend our relationship to almost 20 years. The full range of drilling services included in the contract is not only a reflection of our excellent operational and safety performance, but also highlights our strategy to increase our service offering with long-term mine-site based clients," says Executive Chair Jamie Boyton.

----------

Tristel PLC - Cambridgeshire-based maker of infection prevention, contamination control and hygiene products - Submits its De Novo request for approval to the US Food & Drug Administration for Tristel Duo ULT, a high-level disinfectant foam for ultrasound probes. "Ultrasound probe disinfection is one of Tristel's most important areas of focus within the hospital infection prevention market and accounts for approximately 40% of the company's global revenue, which analysts forecast at GBP28 million for the current financial year," the company says. Says timeframe for FDA decision is 150 days, but additional data requests are commonplace, with the average duration for review and approval is around 11 months.

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
16 May 2019 09:59

4d Pharma To Present Data From Thetanix Clinical Study In San Diego

LONDON (Alliance News) - 4d Pharma PLC on Thursday said it will present the data from the completed phase Ib clinical study of Thetanix for the treatment of Crohn's disease on Saturday in San

Read more
29 Apr 2019 09:20

4d Pharma "Delighted" With Progress Being Made On Oncology Programme

LONDON (Alliance News) - 4d Pharma PLC on Monday reported a positive initial phase of one drug trial and the start of another.In a phase I/II trial of pembrolizumab, or Keytruda, the first

Read more
14 Mar 2019 09:53

DIRECTOR DEALINGS: 4D Pharma CEO And Chief Scientific Officer Buy

LONDON (Alliance News) - 4D Pharma PLC on Thursday said Chief Scientific Officer Alex Stevenson purchased 24,896 shares at a price of 91.5 pence each on Wednesday for a total of in 4D Pharma were

Read more
13 Mar 2019 15:36

DIRECTOR DEALINGS: 4d Pharma Non-Exec Chair And Director Buy Shares

LONDON (Alliance News) - 4d Pharma PLC on Wednesday said Non-Executive Chair David Norwood and Non-Executive Director Thomas Engelen both purchased shares in the AIM-listed pharmaceutical separate

Read more
29 Jan 2019 09:26

4D Pharma Reports Reveals MRx0518 Immune System Stimulatory Effect

LONDON (Alliance News) - 4D Pharma PLC said Tuesday tests have shown its MRx0518 cancer treatment has "strong immuno-stimulatory effects".Researchers at 4D demonstrated that - on

Read more
8 Jan 2019 10:57

4D Pharma Appoints Two Non-Executives From Xencor And Celgene

LONDON (Alliance News) - 4D Pharma PLC said Tuesday it has appointed two new independent non-executive directors, one a previous chief business officer at Xencor Inc and the other a former senior

Read more
7 Jan 2019 08:20

4d Pharma buoyed by Texas cancer treatment partnership

(Sharecast News) - 4d Pharma's shares enjoyed a boost on Monday after entering a collaboration with a specialist cancer unit at the University of Texas.

Read more
7 Jan 2019 07:57

4D Pharma Partners With Cancer Center For Cancer Treatment

LONDON (Alliance News) - 4D Pharma PLC on Monday said it has partnered with the University of Texas MD Anderson Cancer Center to evaluate its live biotherapeutic oncology pipeline.The will

Read more
12 Dec 2018 09:19

4d Pharma "Not Aware Of Matter" Responsible For Drop In Share Price

LONDON (Alliance News) - 4d Pharma PLC on Wednesday noted a recent fall in its share price, but said is not aware of any company-related reasons for the drop.The pharmaceutical company that

Read more
28 Sep 2018 10:41

4d Pharma Interim Loss Holds Steady Despite Rise In R&D Spending

LONDON (Alliance News) - 4d Pharma PLC on Friday said its loss widened only marginally in the first half of the year, despite significantly higher expenses, due to the absence of a non-recurring a

Read more
28 Sep 2018 08:29

4d Pharma losses little changed as trials begin

(Sharecast News) - First-half losses grew slightly at live biotherapeutics developer 4d Pharma as first-half research and development expenses jumped ahead of two of its major treatment candidates receiving clearance for clinical trials.

Read more
24 Sep 2018 14:19

Positive top-line results for 4D Pharma's Thetanix

(Sharecast News) - Biotherapeutics company 4D Pharma announced positive top-line results for its Phase 1b study of 'Thetanix' in paediatric patients with Crohn's disease on Monday.

Read more
24 Sep 2018 08:45

4d Pharma Reports Positive Results From Phase Ib Study Of Thetanix

LONDON (Alliance News) - 4d Pharma PLC on Monday said its phase Ib study of Thetanix in paediatric patients with Crohn's disease achieved its primary objective.Crohn's disease is a

Read more
12 Jun 2018 17:55

Janus Henderson Increases Stake In 4d Pharma To 5.2% (ALLISS)

LONDON (Alliance News) - 4d Pharma PLC said Janus Henderson Group PLC increased stake in the pharmaceutical company to 5.2% after a transaction on Tuesday.Janus Henderson raised its holding

Read more
21 May 2018 07:40

LONDON MARKET PRE-OPEN: FTSE 100 Set For All-Time Record At Open

LONDON (Alliance News) - The FTSE 100 is set to open at an all-time high on Monday, coming after trade tensions between the US and China eased over the weekend.In early UK company news on said the US

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.